title: Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
abstract: OBJECTIVE
  To evaluate the prognostic value of preoperative serum tetranectin (TN) in Danish ovarian cancer (OvCa) patients. Design. Population-based, multidisciplinary Danish case-control study of OvCa.
  
  
  METHODS
  A total of 445 primary OvCa patients diagnosed at one of the gynecological departments in 18 regional hospitals around Denmark during the period 1994-1999.
  
  
  METHODS
  Serum levels of TN were evaluated preoperatively and tested for possible association with prognosis.
  
  
  METHODS
  Disease specific survival.
  
  
  RESULTS
  During the observation period (median 45.9 months, range 0.2-121) 278 OvCa-related deaths were seen. Univariate analysis of TN and CA125 demonstrated a significant association with survival using the Cox proportional hazards model, when stratified for adjuvant treatment (TN: p < 0.0001, hazard ratio = 0.44; 95% confidence interval 0.33-0.60 and CA125: p < 0.0001, hazard ratio = 1.19; 95% confidence interval 1.11-1.27). Disease specific survival curves for patients with tumors in the early stages showed no significant association with survival, neither for TN (p = 0.68) nor for CA125 (p = 0.07). For the stage III group, a significant association with survival was found for TN (p = 0.027), but not for CA125 (p = 0.37). Multivariate Cox analysis identified TN, age, residual tumor, International Federation of Gynecology and Obstetrics stage and grade but not serum CA125 as independent prognostic variables.
  
  
  CONCLUSIONS
  Preoperative serum TN is a useful prognostic indicator of advanced stage for patients with OvCa.
authors.affiliation: The Gynecologic Clinic, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Farah Diba
authors.initials: FD
authors.lastname: Begum
authors.forename: Estrid
authors.initials: E
authors.lastname: Høgdall
authors.forename: Ib Jarle
authors.initials: IJ
authors.lastname: Christensen
authors.forename: Susanne Krüger
authors.initials: SK
authors.lastname: Kjaer
authors.forename: Jan
authors.initials: J
authors.lastname: Blaakaer
authors.forename: Lise
authors.initials: L
authors.lastname: Christensen
authors.forename: Claus
authors.initials: C
authors.lastname: Høgdall
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016022:Case-Control Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D037181:Lectins, C-Type / Q000097:blood*; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000473:pathology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D011300:Preoperative Care; D011379:Prognosis; D016016:Proportional Hazards Models; D012042:Registries
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D037181:Lectins, C-Type; C048648:tetranectin